Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Learn More »

Volume:

Minimum 15 minutes delayed. Source: LSEG

Recent Press Releases

November 16, 2026
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
November 4, 2026
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Upcoming Events